on Dermapharm Holding SE (isin : DE000A2GS5D8)
Dermapharm Reports Stable Business in H1 2025 and Q2 EBITDA Growth
Dermapharm Holding SE, a German pharmaceutical company, has reported stable business development in H1 2025 with significant growth in EBITDA for Q2. The consolidated revenue reached EUR 574.5 million, a slight decrease of 0.7% from the previous year, primarily due to portfolio optimizations in parallel imports. However, the "Branded pharmaceuticals" segment saw a revenue increase of 4.0%, contributing strongly to overall performance.
Despite challenges, Dermapharm's adjusted EBITDA rose by 3.7% in Q2 compared to the prior-year quarter. The company confirmed its full-year guidance, expecting consolidated revenue between EUR 1,160–1,200 million and adjusted EBITDA of EUR 322–332 million. Structural changes in Arkopharma and the parallel import business are reflecting positive outcomes.
The company's CEO, Dr. Hans-Georg Feldmeier, cited operational strength and market positioning within the "Branded pharmaceuticals" segment as key to maintaining growth prospects for the year ahead.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Dermapharm Holding SE news